Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
复制标题
DOI：
10.1136/annrheumdis-2015-207942
复制
发表时间：
2016-04
影响因子：
27.4
通讯作者：
Robinson WH
中科院分区：
文献类型：
--
作者：
Sokolove J;Schiff M;Fleischmann R;Weinblatt ME;Connolly SE;Johnsen A;Zhu J;Maldonado MA;Patel S;Robinson WH
在为期两年的研究(在有甲氨蝶呤背景的生物幼稚类风湿性关节炎受试者中，阿巴坦和阿达单抗的比较)中，检查基线抗环瓜氨酸多肽-2(CCP2)抗体状态和浓度是否与服用背景甲氨蝶呤(MTX)的阿巴坦或阿达单抗治疗患者的临床结果相关。在这项探索性分析中，抗CCP2抗体浓度在基线时被测量，抗体阳性患者被分成四等分，Q1-Q4，代表抗体浓度增加。根据基线抗CCP2状态和四分位数分析的临床结果包括疾病活动性、致残率和缓解率与基线相比的变化。四分位数和治疗组的基线特征大体上具有可比性。在两个治疗组中，抗CCP2抗体阴性的患者的反应不如抗体阳性的患者。在第二年，疾病活动性的改善以及残疾和缓解率在第一季度到第三季度是相似的，但在数字上，abatacept组在第四季度更高；相比之下，adalimumab组的治疗效果在所有四分位数上都是相似的。在大量病例中，基线抗CCP2阳性与对阿巴贝特和阿达单抗有较好的反应相关。基线抗CCP2抗体浓度最高的患者比浓度较低的患者对Abatacept的临床反应更好，这一关联在阿达利单抗中没有观察到。NCT00929864。
To examine whether baseline anti-cyclic citrullinated peptide-2 (CCP2) antibody status and concentration correlated with clinical outcomes in patients treated with abatacept or adalimumab on background methotrexate (MTX) in the 2-year AMPLE (Abatacept versus adaliMumab comParison in bioLogic-naïvE rheumatoid arthritis subjects with background MTX) study. In this exploratory analysis, anti-CCP2 antibody concentration was measured at baseline, and antibody-positive patients were divided into equal quartiles, Q1–Q4, representing increasing antibody concentrations. Clinical outcomes analysed by baseline anti-CCP2 status and quartile included change from baseline in disease activity and disability and remission rates. Baseline characteristics were generally comparable across quartiles and treatment groups. In both treatment groups, anti-CCP2 antibody-negative patients responded less well than antibody-positive patients. At year 2, improvements in disease activity and disability and remission rates were similar across Q1–Q3, but were numerically higher in Q4 in the abatacept group; in contrast, treatment effects were similar across all quartiles in the adalimumab group. In AMPLE, baseline anti-CCP2 positivity was associated with a better response for abatacept and adalimumab. Patients with the highest baseline anti-CCP2 antibody concentrations had better clinical response with abatacept than patients with lower concentrations, an association that was not observed with adalimumab. NCT00929864.